A prognostic model based on tumor microenvironment-related lncRNAs predicts therapy response in pancreatic cancer

Lu, Jianzhong; Tan, Jinhua; Yu, Xiaoqing

doi:10.1007/s10142-023-00964-x

Cited by 5 publications

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the rapid development of diagnosis and therapeutic strategies for malignant tumors, PAAD patients are often diagnosed at a late stage and benefit little from current treatments. Therefore, the development of biomarkers for early diagnosis and risk assessment of pancreatic cancer has important clinical significance (Lu et al 2023 ; Zheng et al 2023 ). Recently, the role of ubiquitination-related regulators in the occurrence and outcome of pancreatic cancer has been deeply researched, which can influence the occurrence, progression, metastasis, and treatment response of various cancers (Ma et al 2020 ; Sun et al 2020 ; Chen et al 2021 ).…”

Section: Discussionmentioning

confidence: 99%

A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo

Wang

Yuan

et al. 2023

Funct Integr Genomics

View full text Add to dashboard Cite

Ubiquitination-related genes (URGs) exerted a crucial part in a variety of human disease disorders; however, their association with pancreatic adenocarcinoma (PAAD) had yet to be clearly described. We aimed to comprehensively characterize the contributions of URGs in PAAD through in silico analysis and experimental validation, and then identified a robust mRNA-lncRNA-based molecular prognostic panel for patients with PAAD using bulk RNA-sequencing and single-cell RNA-sequencing data. Initially, we collected the multi-omics data from TCGA platform to depict a comprehensive landscape of URGs in pan-cancer. Furthermore, we were accurate to PAAD for in-depth analysis. Significant differences of the activation of ubiquitination pathways and the expression of URGs were detected between normal and malignant cells. Unsupervised hierarchical clustering determined two PAAD subtypes with distinct clinical outcomes, ubiquitination pathway activities, immune microenvironment, and functional annotation characteristics. The expression profiles of ubiquitination-associated mRNAs and lncRNAs in the training and validation datasets were utilized to develop and verify a novel ubiquitination-related mRNA-lncRNA prognostic panel, which had a satisfied prediction efficiency. Our ubiquitination-associated model could function as an effective prognostic index and outperformed four other recognized panels in evaluating PAAD patients’ survival status. Tumor immune microenvironment, mutation burden, and chemotherapy response were intensively explored to demonstrate the underlying mechanism of prognostic difference according to our panel. Our findings also revealed that FTI-277, a farnesyltransferase inhibitor, had a better curative effect in high-risk patients, while MK-2206, an Akt allosteric inhibitor, had a superior therapeutic effect in low-risk patients. The real-time PCR results uncovered the RNA expression of AC005062.1 in all the three PAAD cell lines was elevated several thousandfold. In conclusion, our URGs-based classification panel could be triumphantly served as a prediction tool for survival evaluation in patients with PAAD, and the genes in this panel could be developed as a potential target in PAAD therapy.

show abstract